COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
Confluence Life Sciences develops selective, orally active small-molecule kinase inhibitors using its proprietary KINect discovery platform for cancer and inflammatory diseases, and provides contract biological assay development and execution.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors